{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:52:29Z","timestamp":1792266749722,"version":"4.4.0"},"reference-count":68,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hodgkin lymphoma (HL) is a rare hematologic malignancy with a bimodal distribution of incidence, with most patients diagnosed between the ages of 15 and 30 years and another peak in patients older than 55 years. It is estimated that in 2023, almost 9000 people were diagnosed with HL in the United States. Most patients will be cured using conventional chemotherapy and radiotherapy. The treatment of HL has changed significantly over the past decade following the approval of highly effective novel therapies, including brentuximab vedotin and the checkpoint inhibitors (CPIs) nivolumab and pembrolizumab. The increasing use of these novel therapies has resulted in decreased utilization of both autologous and allogeneic hematopoietic cell transplantation (HCT) in patients with HL. In this review, we discuss the role of stem cell transplantation in patients with HL, with a particular focus on recent data supporting allogeneic HCT as a curative option in patients who progress on or are intolerant to CPI treatment.<\/jats:p>","DOI":"10.1182\/hematology.2024000575","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T15:04:59Z","timestamp":1733497499000},"page":"517-523","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["When to use stem cell transplantation for classical Hodgkin lymphoma"],"prefix":"10.1182","volume":"2024","author":[{"given":"Miguel-Angel","family":"Perales","sequence":"first","affiliation":[{"name":"1 Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2 Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[{"name":"3 Department of Lymphoma\/Myeloma and Department of Stem Cell Transplantation\/Cellular Therapy, MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"issue":"19","key":"2024121115511920500_hem2024000575C1","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"issue":"18","key":"2024121115511920500_hem2024000575C2","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9980","key":"2024121115511920500_hem2024000575C3","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"issue":"8","key":"2024121115511920500_hem2024000575C4","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1182\/blood-2014-08-595801","article-title":"Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Gopal","year":"2015","journal-title":"Blood"},{"issue":"21","key":"2024121115511920500_hem2024000575C5","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1182\/blood.V124.21.289.289","article-title":"Nivolumab in patients with relapsed or refractory Hodgkin lymphoma\u2014preliminary safety, efficacy and biomarker results of a phase I study","volume":"124","author":"Armand","year":"2014","journal-title":"Blood"},{"issue":"14","key":"2024121115511920500_hem2024000575C6","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"issue":"31","key":"2024121115511920500_hem2024000575C7","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"issue":"19","key":"2024121115511920500_hem2024000575C8","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"2024121115511920500_hem2024000575C9","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.bbmt.2015.02.022","article-title":"Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Perales","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2024121115511920500_hem2024000575C10","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.bbmt.2005.09.009","article-title":"Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol","volume":"12","author":"Alvarez","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2024121115511920500_hem2024000575C11","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JCO.20.01447","article-title":"Is there still a role for allogeneic transplantation in the management of lymphoma?","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"issue":"9","key":"2024121115511920500_hem2024000575C12","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.bbmt.2019.05.025","article-title":"Lower graft-versus-host disease and relapse risk in post-transplant cyclophosphamide-based haploidentical versus matched sibling donor reduced-intensity conditioning transplant for Hodgkin lymphoma","volume":"25","author":"Ahmed","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2024121115511920500_hem2024000575C13","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/bjh.16664","article-title":"Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma","volume":"190","author":"Ahmed","year":"2020","journal-title":"Br J Haematol"},{"issue":"9","key":"2024121115511920500_hem2024000575C14","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"issue":"14","key":"2024121115511920500_hem2024000575C15","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"issue":"28","key":"2024121115511920500_hem2024000575C16","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.21.01056","article-title":"Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma","volume":"39","author":"Moskowitz","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"2024121115511920500_hem2024000575C17","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1182\/hematology.2022000365","article-title":"Do all patients with primary refractory\/first relapse of HL need autologous stem cell transplant?","volume":"2022","author":"Moskowitz","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"23","key":"2024121115511920500_hem2024000575C18","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J Clin Oncol"},{"issue":"11","key":"2024121115511920500_hem2024000575C19","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1159\/000481800","article-title":"Checkpoint inhibition in Hodgkin lymphoma\u2014a review","volume":"40","author":"Br\u00f6ckelmann","year":"2017","journal-title":"Oncol Res Treat"},{"issue":"11","key":"2024121115511920500_hem2024000575C20","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"},{"issue":"34","key":"2024121115511920500_hem2024000575C21","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1200\/JCO.2010.30.5771","article-title":"Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma","volume":"28","author":"Josting","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"2024121115511920500_hem2024000575C22","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00277-016-2619-9","article-title":"Prognostic value of pretransplant FDG-PET in refractory\/ relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis","volume":"95","author":"Adams","year":"2016","journal-title":"Ann Hematol"},{"issue":"3","key":"2024121115511920500_hem2024000575C23","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/ajh.26827","article-title":"Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed\/refractory classic Hodgkin lymphoma","volume":"98","author":"Desai","year":"2023","journal-title":"Am J Hematol"},{"issue":"12","key":"2024121115511920500_hem2024000575C24","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.bbmt.2015.07.018","article-title":"Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed\/refractory Hodgkin lymphoma","volume":"21","author":"Chen","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2024121115511920500_hem2024000575C25","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/annonc\/mdz009","article-title":"Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)","volume":"30","author":"Garcia-Sanz","year":"2019","journal-title":"Ann Oncol"},{"issue":"8","key":"2024121115511920500_hem2024000575C26","doi-asserted-by":"crossref","first-page":"e562","DOI":"10.1016\/S2352-3026(21)00170-8","article-title":"Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase \u00bd study","volume":"8","author":"Lynch","year":"2021","journal-title":"Lancet Haematol"},{"issue":"4","key":"2024121115511920500_hem2024000575C27","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3324\/haematol.2019.243238","article-title":"Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON\/LLPC Transplant BRaVE study","volume":"106","author":"Kersten","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"2024121115511920500_hem2024000575C28","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2024121115511920500_hem2024000575C29","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"issue":"25","key":"2024121115511920500_hem2024000575C30","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1182\/blood.2022015423","article-title":"Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE","volume":"139","author":"Mei","year":"2022","journal-title":"Blood"},{"issue":"8852","key":"2024121115511920500_hem2024000575C31","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"issue":"9323","key":"2024121115511920500_hem2024000575C32","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"2024121115511920500_hem2024000575C33","first-page":"CD009411","article-title":"High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed\/refractory Hodgkin lymphoma","volume":"6","author":"Rancea","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"15","key":"2024121115511920500_hem2024000575C34","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1200\/JCO.2006.10.1386","article-title":"Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma","volume":"25","author":"Sieniawski","year":"2007","journal-title":"J Clin Oncol"},{"issue":"11","key":"2024121115511920500_hem2024000575C35","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/00043426-200411000-00010","article-title":"Outcome after autologous hemopoietic stem cell transplantation in relapsed or refractory childhood Hodgkin disease","volume":"26","author":"Stoneham","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"issue":"25","key":"2024121115511920500_hem2024000575C36","doi-asserted-by":"crossref","first-page":"6181","DOI":"10.1200\/JCO.2005.07.930","article-title":"Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL\/GPOH-HD study group","volume":"23","author":"Schellong","year":"2005","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2024121115511920500_hem2024000575C37","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1182\/blood-2021-148139","article-title":"A phase II single arm study of nivolumab as maintenance therapy after autologous stem cell transplantation in patients with Hodgkin lymphoma at risk of relapse or progression","volume":"138","author":"Bachier","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2024121115511920500_hem2024000575C38","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.2019000215","article-title":"PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation","volume":"134","author":"Armand","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2024121115511920500_hem2024000575C39","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2352-3026(22)00318-0","article-title":"Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial","volume":"10","author":"Herrera","year":"2023","journal-title":"Lancet Haematol"},{"issue":"18","key":"2024121115511920500_hem2024000575C40","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood-2009-12-253856","article-title":"Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability","volume":"115","author":"Sarina","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2024121115511920500_hem2024000575C41","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1093\/annonc\/mdt206","article-title":"Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation","volume":"24","author":"Mart\u00ednez","year":"2013","journal-title":"Ann Oncol"},{"issue":"2","key":"2024121115511920500_hem2024000575C42","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3324\/haematol.2011.045757","article-title":"Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study\u2014a prospective clinical trial by the Grupo Espanol de Linfomas\/Trasplante de Medula Osea (GEL\/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"97","author":"Sureda","year":"2012","journal-title":"Haematologica"},{"issue":"2","key":"2024121115511920500_hem2024000575C43","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3324\/haematol.11828","article-title":"Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience","volume":"93","author":"Anderlini","year":"2008","journal-title":"Haematologica"},{"issue":"2","key":"2024121115511920500_hem2024000575C44","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3324\/haematol.13441","article-title":"Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome","volume":"94","author":"Robinson","year":"2009","journal-title":"Haematologica"},{"issue":"1","key":"2024121115511920500_hem2024000575C45","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bbmt.2008.11.011","article-title":"Unrelated donor reduced- intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"15","author":"Devetten","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2024121115511920500_hem2024000575C46","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/bmt.2016.349","article-title":"Reduced-intensity and non- myeloablative allogeneic stem cell transplantation from alternative HLA- mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy","volume":"52","author":"Gauthier","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2024121115511920500_hem2024000575C47","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/ajh.23897","article-title":"The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"90","author":"Kako","year":"2015","journal-title":"Am J Hematol"},{"issue":"1","key":"2024121115511920500_hem2024000575C48","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1186\/s12885-020-07602-w","article-title":"Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients","volume":"20","author":"Castagna","year":"2020","journal-title":"BMC Cancer"},{"issue":"2","key":"2024121115511920500_hem2024000575C49","doi-asserted-by":"crossref","first-page":"210.e1","DOI":"10.1016\/j.jtct.2023.11.021","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis in HLA-matched and haploidentical donor transplantation for patients with Hodgkin lymphoma: a comparative study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation","volume":"30","author":"Montoro","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"2024121115511920500_hem2024000575C50","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/bmt.2016.357","article-title":"Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin era","volume":"52","author":"Hegerova","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2024121115511920500_hem2024000575C51","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/bjh.15152","article-title":"Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party","volume":"181","author":"Bazarbachi","year":"2018","journal-title":"Br J Haematol"},{"issue":"1","key":"2024121115511920500_hem2024000575C52","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbmt.2018.08.028","article-title":"Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation","volume":"25","author":"Ijaz","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2024121115511920500_hem2024000575C53","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/ refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2024121115511920500_hem2024000575C54","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1038\/s41375-021-01193-6","article-title":"Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma","volume":"35","author":"Merryman","year":"2021","journal-title":"Leukemia"},{"issue":"7","key":"2024121115511920500_hem2024000575C55","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1182\/bloodadvances.2019001336","article-title":"Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma","volume":"4","author":"De Philippis","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"2024121115511920500_hem2024000575C56","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/bmt.2015.332","article-title":"Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis","volume":"51","author":"Rashidi","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2024121115511920500_hem2024000575C57","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1200\/JCO.1996.14.4.1291","article-title":"Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease","volume":"14","author":"Milpied","year":"1996","journal-title":"J Clin Oncol"},{"issue":"12","key":"2024121115511920500_hem2024000575C58","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1182\/blood-2004-01-0231","article-title":"Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry","volume":"104","author":"Freytes","year":"2004","journal-title":"Blood"},{"issue":"12","key":"2024121115511920500_hem2024000575C59","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1093\/annonc\/mdw421","article-title":"Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed\/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"27","author":"Genadieva-Stavrik","year":"2016","journal-title":"Ann Oncol"},{"issue":"7","key":"2024121115511920500_hem2024000575C60","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1001\/jamaoncol.2020.1278","article-title":"Association of reduced-intensity conditioning regimens with overall survival among patients with non-Hodgkin lymphoma undergoing allogeneic transplant","volume":"6","author":"Ghosh","year":"2020","journal-title":"JAMA Oncol"},{"issue":"4","key":"2024121115511920500_hem2024000575C61","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41409-017-0018-z","article-title":"Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin's lymphoma undergoing allogeneic haematopoietic cell transplantation\u2014a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy","volume":"53","author":"Gauthier","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"30","key":"2024121115511920500_hem2024000575C62","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1200\/JCO.2017.72.6869","article-title":"Post-transplantation cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for Hodgkin lymphoma: a registry study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation","volume":"35","author":"Mart\u00ednez","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"2024121115511920500_hem2024000575C63","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.bbmt.2008.08.014","article-title":"Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma","volume":"14","author":"Burroughs","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2024121115511920500_hem2024000575C64","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/s41409-019-0754-3","article-title":"Is this real life? Is this just fantasy? Decreased relapse following haploidentical transplant in Hodgkin's lymphoma with posttransplant cyclophosphamide","volume":"55","author":"Mussetti","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2024121115511920500_hem2024000575C65","doi-asserted-by":"crossref","first-page":"184.e1","DOI":"10.1016\/j.jtct.2022.11.028","article-title":"Haploidentical versus matched unrelated donor transplants using post-transplantation cyclophosphamide for lymphomas","volume":"29","author":"Mussetti","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"18","key":"2024121115511920500_hem2024000575C66","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.20.03502","article-title":"National marrow donor program-sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide","volume":"39","author":"Shaw","year":"2021","journal-title":"J Clin Oncol"},{"issue":"15","key":"2024121115511920500_hem2024000575C67","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1182\/bloodadvances.2022007596","article-title":"Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant","volume":"6","author":"Jimenez-Jimenez","year":"2022","journal-title":"Blood Adv"},{"issue":"25","key":"2024121115511920500_hem2024000575C68","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/517\/2346820\/517perales.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/517\/2346820\/517perales.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T20:26:41Z","timestamp":1733948801000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2024\/1\/517\/526234\/When-to-use-stem-cell-transplantation-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,6]]},"published-print":{"date-parts":[[2024,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2024000575","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12,6]]},"published":{"date-parts":[[2024,12,6]]}}}